BASEL, SWITZERLAND – Roche Holding AG received official permission from the U.S. Federal Trade Commission for its proposed acquisition of Corange Ltd., the parent company of Boehringer Mannheim and DePuy.
BASEL, SWITZERLAND â Roche Holding AG received official permission from the U.S. Federal Trade Commission for its proposed acquisition of Corange Ltd., the parent company of Boehringer Mannheim and DePuy.
FTC approval, however, is couched between two conditions. The takeover must not give Roche a dominant position in the thrombolytic market, the FTC insisted, and Roche must sell Boehringer Mannheim's drugs-of-abuse-testing business after the takeover.
To meet these requirements, Roche will sell the U.S. and Canadian rights to Boehringer Mannheim's myocardial infarction medicine, Retavase,® to Centocor Inc., and will seek a buyer for Boehringer Mannheim's CEDIA line of abuse-testing drugs.
The merger, first suggested last spring, was cleared by the European Commission, the agency that enforces antitrust policies for the European Union, earlier in February. Switzerland, Canada and Australia had also indicated their approval of the merger.
The European Union Commission reached its decision approximately three weeks ahead of the FTC and imposed some of its own terms. First, the commission said, Roche must make use of the technology in its in vitro diagnostics accessible to additional competitors. Terms of the approval called for a licensing agreement covering all diagnostic applications as well as the use of PCR in diagnosing individual diseases. Second, Roche must divest its rights to the Cobas MIRA® line of clinical chemistry analyzers in the European Union. The company may retain its rights to the business in all other markets worldwide, the commission allowed.
The acquisition, which was made formally possible 10 working days after FTC approval, should position Roche as a global leader in diagnostics. It will also strengthen its pharmaceutical division, the foundation of Roche's operations. According to company statements, the pharmaceutical division accounts for more than 60% of business. In 1997, for example, it accounted for more than $7.9 billion of the company's approximate $13.2 billion in consolidated sales. PR
The Transformative Role of Medical Information in Customer Engagement
October 3rd 2024Stacey Fung, Head of Global Medical Information at Gilead Lifesciences, delves into the evolving role of Medical Information (MI) in the pharmaceutical industry. Covering key topics like patient engagement through omnichannel strategies, combating misinformation, and leveraging AI to enhance medical inquiries, the conversation with Stacey highlights MI's critical role in ensuring patient safety and supporting drug development. She also shares her professional journey and tidbits for early career professionals on professional development.
Unlocking value and cost savings in patient services with technology and talent
October 2nd 2024Traci Miller, Director, Sonexus™ Access and Patient Support, Cardinal Health, discusses the current digital trends in the patient services industry and how the optimal balance of technology and talent can transform manufacturer-sponsored patient support programs. Hear how Cardinal Health combines best-in-class program and pharmacy operations with smart digital tools to ensure product and patient success and reduce operational costs.